Skip to main content

Laboratory Corporation of America Holdings Value Stock - Dividend - Research Selection

Laboratory

ISIN: US50540R4092 , WKN: 895308

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women\'s health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests. Laboratory Corporation of America Holdings was founded in 1971 and is headquartered in Burlington, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update

2026-09-09
The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.

Labcorp Acquires MLM Medical Labs, Expanding Global Central Laboratory and Biomarker Capabilities for Clinical Trials

2026-09-08
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa. Financial terms of the transaction were not disclosed.

Labcorp Acquires MLM Medical Labs; Financial Terms Not Disclosed

2026-09-08
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the acquisition of MLM Medical Labs (MLM), a leading global central and specialty laboratory provider with

Market Shocks Are Not Where Hims & Hers Health Stock Has Fallen Furthest

2026-08-31
Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Labcorp Launches Next Generation of Labcorp Global Trial Connect™ to Help Sponsors and Investigator Sites Navigate Clinical Trial Complexity

2026-08-31
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory solutions, today announced enhancements to the digital experience of Labcorp Global Trial Connect™, the company's portfolio of clinical trial services, data and technology that enhances and accelerates delivery. The newly redesigned platform introduces new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences of Global Trial Connect, providing greater visibility across studies, simplify

Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-28
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, at 11:30 a.m. ET.

Labcorp Holdings (LH) Unveiled The First FDA Cleared Single Biomarker Alzheimer’s Blood Test

2026-08-28
Labcorp Holdings (NYSE: LH) introduced the Elecsys pTau-217 blood test, the first FDA-cleared single biomarker test for Alzheimer’s disease, expanding access through primary and specialty care. The Elecsys pTau-217 test is positioned to support clinical assessment of cognitive decline with a minimally invasive blood draw instead of more invasive procedures. Labcorp announced a long-term alliance with the National Association of Community Health Centers to support clinical leadership and...

Are Wall Street Analysts Bullish on Labcorp Holdings Stock?

2026-08-26
Do Wall Street analysts favor Labcorp’s stock, given its solid performance?

3 Reasons LH is Risky and 1 Stock to Buy Instead

2026-08-25
Over the past six months, Labcorp has been a great trade, beating the S&P 500 by 9.5%. Its stock price has climbed to $339.34, representing a healthy 20% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

2026-08-25
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.